News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
GlaxoSmithKline and Genmab A/S Announce Start of Ofatumumab Phase III Combination Study in Non-Hodgkin’s Lymphoma
September 9, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON and COPENHAGEN, Denmark, Sept. 8, 2010 (GLOBE NEWSWIRE) -- Summary: GSK and Genmab announce the initiation of a Phase III study of ofatumumab in rituximab refractory patients with indolent B-cell non-Hodgkin's Lymphoma.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 3
Europe
GlaxoSmithKline
MORE ON THIS TOPIC
Weight loss
Regeneron’s Weight Loss Partner Hansoh Delivers Much-Needed Phase 3 Win in China
March 9, 2026
·
2 min read
·
Annalee Armstrong
Breast cancer
Roche Breast Cancer Prospect Fails First-Line Test, Shares Fall
March 9, 2026
·
2 min read
·
Annalee Armstrong
Drug Development
Xenon To Seek Approval of First-in-Class Epilepsy Drug After Exceeding Phase 3 Expectations
March 9, 2026
·
3 min read
·
Heather McKenzie
Cancer
Ipsen Pulls Cancer Drug Amid Risk of Secondary Malignancies
March 9, 2026
·
2 min read
·
Tristan Manalac
